Syndax Pharmaceuticals Inc. has disclosed recent stock transactions by Dennis Podlesak, a director at the company, in a filing with the SEC. This report is significant as it underscores the company's commitment to transparency and regulatory compliance.

Syndax Pharmaceuticals Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as a large accelerated filer on the Nasdaq under the ticker SNDX. The company is based in New York, with its business address at 730 Third Avenue, 9th Floor.

According to the filing dated October 30, 2026, Podlesak executed two transactions on October 29, 2026. The first transaction involved acquiring 8,000 shares of common stock at a price of $11.81 per share. Following this acquisition, Podlesak now holds a total of 247,763 shares. The second transaction reported a sale of 8,000 shares at a price range between $14.00 and $14.59 per share, bringing his total shares owned down to 239,763.

The filing also notes that the sales were conducted under a Rule 10b5-1 plan, which allows for pre-scheduled trades to be made without concerns of insider trading. Following these transactions, Podlesak retains 127,000 options to purchase shares of common stock that are vested and immediately exercisable.

This update may impact various stakeholders, including investors and analysts who monitor insider trading activities as indicators of company health and management confidence. Transparency in such transactions is crucial for maintaining investor trust and market integrity.

The filing does not specify any future actions or upcoming filings related to these transactions.